Though still considered "correctable" by company execs, the manufacturing troubles that have beset lead acute myeloid leukemia (AML) candidate APTO-253 since late 2015 prompted Aptose Biosciences Inc. to make the tough decision to shift its resources to a preclinical-stage AML asset in-licensed last year.